AHA blog: PhRMA-led coalition seeks to dismantle 340B at patients’ expense

The Pharmaceutical Research and Manufacturers of America’s new ASAP 340B coalition “is another misguided attempt by drug companies to dismantle the 340B Drug Pricing Program so that they can continue to pad their billion-dollar bottom lines,” writes Bharath Krishnamurthy, director of health analytics and policy for the AHA. “The self-serving policy proposals outlined by this new alliance directly contravene Congress’ oft-demonstrated intent to preserve the 340B program over the last 30 years. Those most impacted by this coalition’s assault on 340B are the millions of patients who will lose access to lifesaving medicines and to other vital health care services supported by the program.” READ MORE